Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1432-0843
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO) ; volume:64 ; number:4 ; day:24 ; month:1 ; year:2009 ; pages:769-775 ; date:9.2009
Cancer chemotherapy and pharmacology ; 64, Heft 4 (24.1.2009), 769-775, 9.2009
- Urheber
-
Brandes, Alba A.
Tosoni, A.
Franceschi, E.
Blatt, V.
Santoro, A.
Faedi, M.
Amistà, P.
Gardiman, M.
Labianca, R.
Bianchini, C.
Ermani, M.
Reni, M.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00280-009-0926-8
- URN
-
urn:nbn:de:101:1-2021090120515230486392
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:29 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Brandes, Alba A.
- Tosoni, A.
- Franceschi, E.
- Blatt, V.
- Santoro, A.
- Faedi, M.
- Amistà, P.
- Gardiman, M.
- Labianca, R.
- Bianchini, C.
- Ermani, M.
- Reni, M.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol
Il Gruppo Familiare
Skulptur "Gruppo Mitriaco"
Gruppo Della Galita
Concomitant Temozolomide plus radiotherapy for high-grade and recurrent meningioma: a retrospective chart review
Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years
Laokoongruppe - Gruppo del Laoconte
Patterns, predictors and prognostic relevance of high-grade hematotoxicity after temozolomide or temozolomide-lomustine in the CeTeG/NOA-09 trial
Temozolomide Alone or Combined with Capecitabine for the Treatment of Advanced Pancreatic Neuroendocrine Tumor
Vereinsregisterakte: Gruppo Culturale Italo-Tedesco
Sulle Generatrici del Gruppo Simmetrico.
Due, [...]. Edizione internazionale / Gruppo Meta
Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol
Il Gruppo Familiare
Skulptur "Gruppo Mitriaco"
Gruppo Della Galita
Concomitant Temozolomide plus radiotherapy for high-grade and recurrent meningioma: a retrospective chart review
Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years
Laokoongruppe - Gruppo del Laoconte
Patterns, predictors and prognostic relevance of high-grade hematotoxicity after temozolomide or temozolomide-lomustine in the CeTeG/NOA-09 trial
Temozolomide Alone or Combined with Capecitabine for the Treatment of Advanced Pancreatic Neuroendocrine Tumor
Vereinsregisterakte: Gruppo Culturale Italo-Tedesco
Sulle Generatrici del Gruppo Simmetrico.
Due, [...]. Edizione internazionale / Gruppo Meta
Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol
Il Gruppo Familiare
Skulptur "Gruppo Mitriaco"
Gruppo Della Galita
Concomitant Temozolomide plus radiotherapy for high-grade and recurrent meningioma: a retrospective chart review
Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years
Laokoongruppe - Gruppo del Laoconte
Patterns, predictors and prognostic relevance of high-grade hematotoxicity after temozolomide or temozolomide-lomustine in the CeTeG/NOA-09 trial
Temozolomide Alone or Combined with Capecitabine for the Treatment of Advanced Pancreatic Neuroendocrine Tumor
Vereinsregisterakte: Gruppo Culturale Italo-Tedesco
Sulle Generatrici del Gruppo Simmetrico.